In a report issued on January 4, Steven Valiquette from Barclays maintained a Buy rating on Humana Inc (HUM), with a price target of $351. The company’s shares closed on Friday at $276.62.
According to TipRanks.com, Valiquette is a 4-star analyst with an average return of 4.1% and a 48.2% success rate. Valiquette covers the Services sector, focusing on stocks such as AmerisourceBergen Corporation, Patterson Companies Inc, and WellCare Health Plans.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Humana Inc with a $379.50 average price target, representing a 37.2% upside. In a report issued on December 20, J.P. Morgan also upgraded the stock to Buy with a $333 price target.
.
See today’s analyst top recommended stocks >>
Humana Inc’s market cap is currently $37.95B and has a P/E ratio of 25.47. The company has a Price to Book ratio of 3.58.
Based on the recent corporate insider activity of 68 insiders, corporate insider sentiment is negative on the stock. Most recently, in November 2018, Timothy Huval, the Chief HR Officer of HUM sold 5,165 shares for a total of $1,777,845.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Humana Inc. is a health and well-being company focused on making it easy for people to achieve best health. Its strategy integrates care delivery, the member experience, and clinical & consumer insights to encourage engagement, behavior change, proactive clinical outreach, and wellness for the people.
